Company: DMAC
Filing Date: 2025-11-13
Form Type: S-8
Source: 0001437749-25-034866
Chunk: 1

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-11-13
Form: S-8
Chunk 1
---
 the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

<div align='center'>DIAMEDICA THERAPEUTICS INC.

STATEMENT PURSUANT TO GENERAL INSTRUCTION E
TO FORM S-8“REGISTRATION OF ADDITIONAL SECURITIES”</div>

This Registration Statement on Form S-8 (the “Registration Statement”) relates to the registration of 1,000,000 voting common shares, no par value per share (“Common Shares”), of DiaMedica Therapeutics Inc. (the “Company”) issuable to eligible individuals pursuant to awards granted under the DiaMedica Therapeutics Inc. 2021 Employment Inducement Incentive Plan (the “Plan”). The Company previously filed a registration statement on Form S-8 (File No. 333-263543) relating to the Plan (the “Initial Registration Statement”).

On July 31, 2025, the Company’s Board of Directors amended the Plan, pursuant to which the Company reserved an additional 1,000,000 Common Shares to be used exclusively for grants of equity-based awards to individuals who were not previously employees or directors of the Company, as an inducement to the individual’s entry into employment with the Company within the meaning of Nasdaq Listing Rule 5635(c)(4). The Plan provides for the grant of equity-based awards in the form of stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, or other stock-based awards. The Plan was initially adopted and subsequently amended and restated without shareholder approval in reliance upon Nasdaq Listing Rule 5635(c)(4).

Pursuant to General Instruction E to Form S-8, the contents of the Initial Registration Statement, together with all exhibits filed therewith or incorporated therein by reference, are incorporated herein by reference except to the extent that such information is superseded by the Items appearing below.

<div align='center'>PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>

Item 8. Exhibits.

| Exhibit 
 Number  
 4.1     
 4.2     |     | Description of Exhibit                                                                                                                                                                                  
 Notice of Articles of DiaMedica Therapeutics Inc. dated May 20, 2025 (incorporated by reference to Exhibit 3.1 to quarterly report on Form 10-Q for the quarter ended June 30,